Ocugen Investoren 2022 WKN: A2PSZH ISIN: US67577C1053 Forum: Aktien User: Ad_Astra

SpiegelOnline heute 11.57h: USA: 1,2 Millionen neue Infizierte an einem Tag. In den USA steigt die Zahl der nachgewiesenen Infektionsfälle rasant an. Binnen 24 Stunden wurden den Gesundheitsbehörden mehr als 1,21 Millionen neue Fälle gemeldet. Das ergibt eine Reuters-Zählung auf Basis offizieller Daten. Am Vortag waren es noch rund 837.000 Neuinfektionen. Insgesamt sind damit 59,52 Millionen Ansteckungsfälle bekannt. Mindestens 2506 weitere Menschen starben mit oder an dem Coronavirus. Damit erhöht sich die Zahl der Todesfälle binnen eines Tages auf mindestens 839.476. Weltweit weisen die USA die höchsten Ansteckungs- und Totenzahlen auf. Die Kurve der Neuinfektionen verlaufe »fast senkrecht«, sagt der der US-Virologe Anthony Fauci, der auch Präsident Joe Biden berät.

Omicron kommt bald

COVAXIN Booster Dose 💉💉💉 1⃣3rd dose leads 5X antibodies 🆚 2 dose 2⃣3rd Dose neutralising all variants (Omicron results 🔜) 3⃣Increase in Breadth & Depth of Immune responses 3⃣No safety concerns/favourable risk-benefit profile 4⃣Long term T&B cell responses after 2 doses.

Covaxin Booster Dose Safe and Highly Immunogenic (against all variants) #covaxin #BharatBiotech #COVID19Vaccine #COVID19 #boosterdose #SARS_CoV_2

https://twitter.com/bharatbiotech/status/1479800788335542273?s=21

Booster

https://twitter.com/BharatBiotech/status/1479800788335542273?s=20

https://twitter.com/bharatbiotech/status/1479797790041513984?s=21

Sean Lee -- Citi -- Analyst My first one is on the supply agreement with Bharat. So does that cover a potential commercial supply, if you're EUA for the pediatric population is approved? How much supply would you have access to and also in terms of the tech transfer to Jubilant? What's the progress on and the expected timeline on that? Shankar Musunuri -- Chairman and Chief Executive Officer Yes, upon EUA, our supply agreement does include adequate doses, Sean, and our partners have significantly increased that capacity this year. And also so that they don't how many restrictions for export. So we will be -- we'll get adequate supply whatever is needed post EUA in the US. And as for as technology transfer is concerned at Jubilant HollisterStier, the program is going well and we are anticipating completion of establishing that including process validations in the first half of next year. So that, we can switch the supply and so the initial part of the supply does include -- even we did see a product from biotech our partners it will include US packaging and the testing from the US release site, which have been established. Sean Lee -- Citi -- Analyst Once the tech transfer is completed next year, would you need additional CMC validation from the FDA to show that the clinical batch and the commercial batch of the same? Shankar Musunuri -- Chairman and Chief Executive Officer Yeah. That's a normal part of the process when you add an additional site, you always have to show the compatibility and that would be the product process.

Neverending Story